From June 23rd to June 26th, CHITOSE participated in the 28th European Society for Animal Cell Technology (ESACT) conference in Edinburgh, Scotland. The event, centered on the latest developments in animal cell technology, featured academic workshops, networking, and educational sessions, providing a platform for participants to present their research through poster and short talk sessions while also connecting with other professionals in the industry. Attendees came from diverse sectors, including pharmaceuticals, bioventures, academia, CDMO, culture medium manufacturing, and device companies.

From left to right: BioEngineer Erike Widyasari Sukowati, BioEngineer Yu-Hsin Chang and Senior Manager Riztyan from Tech & Biz Development Div.

CHITOSE was chosen to showcase its recent advancements in mammalian cell technology during the poster presentations on June 24th. BioEngineer Yu-Hsin Chang introduced CHITOSE newly established human amniotic epithelial cell line for gene and cell therapy (HAT) (*1). The novel HAT cells present a promising alternative as hosts for production of recombinant AAV vectors for gene therapy. The presentation covered the high-yield AAV production and high proportion of full particles and highlighted the success of scale-up of AAV production at 10 L scale in HAT cells. 

The second poster presentation, delivered by BioEngineer Erike Widyasari Sukowati, introduced CHITOSE novel CHO cell line, named CHO-MK cells (*2). These cells exhibit an excellent doubling time of less than 10 hours and a growth rate twice as fast as conventional CHO cells. Moreover, the optimal culture strategy using CHO-MK cells resulted in an astonishing productivity of 10 g/L on day 5. This advancement holds significant potential for enhancing the efficiency and scalability of therapeutic protein production in a short culture period.

CHITOSE’s poster presentations of high-performing mammalian cell solutions attracted significant attention from visitors from both industry and academia, laying the groundwork for future business opportunities. Additionally, the networking events provided an excellent platform for exchanging ideas and exploring collaborative projects with other participants. CHITOSE will leverage the knowledge and connections gained from this event to continue contributing to the global biologics industry.

*1 HAT cells resulted from research supported by AMED under Grant Number JP18ae0201001.
*2 The establishment of CHO-MK cells was supported by AMED under the Grant Number JP18ae0101054.

Event overview:
Event name: European Society for Animal Cell Technology 2024
Date: June 23rd (Sunday) – June 26th (Wednesday), 2024
Venue: Edinburgh International Conference Centre

Related Articles
Stable Cell Line Development Service for Biopharmaceutical Production
[External] ESACT2024
[External] Establishment of a novel cell line, CHO-MK, derived from Chinese hamster ovary tissues for biologics manufacturing